NCT07146685 Effect of Local Anesthetic Concentration on Rebound Pain
| NCT ID | NCT07146685 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | University of Virginia |
| Condition | Rebound Pain |
| Study Type | INTERVENTIONAL |
| Enrollment | 10 participants |
| Start Date | 2026-05-13 |
| Primary Completion | 2028-01-28 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 10 participants in total. It began in 2026-05-13 with a primary completion date of 2028-01-28.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Randomized control study that compares different concentrations of local anesthetic to investigate whether a lower concentration of local anesthetic would contribute to lower rebound pain scores at 24 hours post op in patients undergoing anatomic or reverse total shoulder arthroplasty.
Eligibility Criteria
Inclusion Criteria: * Total shoulder replacement patients (anatomic and reverse) * Adult patients (greater than or equal to 18 years) * Any gender * Any race Exclusion Criteria: * \- Chronic Pain diagnoses including: * substance/opioid use disorder * complex regional pain syndromes * fibromyalgia * Daily persistent opioid use spanning 3 months prior to surgery date * Allergy to local anesthetics or NSAIDS * Respiratory pathologies including: * CPAP- non-compliant / untreated obstructive sleep apnea * COPD * Restrictive lung disease (pulmonary fibrosis, interstitial pneumonia, etc) * Contralateral diaphragm dysfunction * BMI \> 40 * Ipsilateral extremity pre-existing nerve injury * GFR \< 60 * NSAID contraindications * Inability to follow up * Revision surgery * Patients requesting block as primary (avoidance of general anesthesia) * Need or request for brachial plexus catheter or liposomal bupivacaine * Vulnerable populations (pregnancy, incarceration, etc) * non-English speaking
Contact & Investigator
Leon N Grinman, DO
PRINCIPAL INVESTIGATOR
UVA
Frequently Asked Questions
Who can join the NCT07146685 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Rebound Pain. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07146685 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07146685 currently recruiting?
Yes, NCT07146685 is actively recruiting participants. Contact the research team at Lngrinman@gmail.com for enrollment information.
Where is the NCT07146685 trial being conducted?
This trial is being conducted at Charlottesville, United States.
Who is sponsoring the NCT07146685 clinical trial?
NCT07146685 is sponsored by University of Virginia. The principal investigator is Leon N Grinman, DO at UVA. The trial plans to enroll 10 participants.